MyFinsight
Home
Blog
About
Contact
Download
Download image
Proceeds from issuance of
common stock in...
$80,657K
Proceeds from issuance of
common stock upon...
$3,205K
Proceeds from employee
stock purchase plan
$465K
Proceeds from maturity of
marketable securities
$60,900K
Net cash provided by
financing activities
$84,327K
Net cash used in
investing activities
$50,694K
Canceled cashflow
$10,206K
Net increase in
cash, cash...
$74,439K
Canceled cashflow
$60,582K
Stock-based compensation
expense
$8,753K
Accounts receivable
-$1,486K
Reduction in the carrying
amount of right of use...
$608K
Depreciation
$439K
Purchases of marketable
securities
$9,853K
Purchases of property and
equipment
$353K
Net cash (used in)
provided by operating...
-$60,582K
Canceled cashflow
$11,286K
Net (loss) income
-$50,003K
Accounts payable,
accrued liabilities and...
-$15,719K
Prepaid expenses and
other current assets
$3,588K
Deferred revenue
-$2,193K
Amortization and accretion of
marketable securities
-$365K
Back
Back
Cash Flow
Stoke Therapeutics, Inc. (STOK)
Stoke Therapeutics, Inc. (STOK)
source: myfinsight.com